We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Bệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemia
MedXY News
EnglishTag

Bệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemia

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligenceclinical trialstype 1 diabetesHypertensiononcologyCardiologypublic healthdiabetesMortalitycardiovascular diseaseAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease
Hematology-OncologyBệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemiadel(17p)

Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease

By MedXY|Oct 6, 2026

A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies

Long-Term Efficacy and Safety of First-Line Ibrutinib-Venetoclax in Older Patients with Chronic Lymphocytic Leukemia: Insights from the 67-Month GLOW Study
Hematology-Oncology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
adverse events
Bệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemia

Long-Term Efficacy and Safety of First-Line Ibrutinib-Venetoclax in Older Patients with Chronic Lymphocytic Leukemia: Insights from the 67-Month GLOW Study

By MedXY|Oct 5, 2026

The GLOW phase III trial demonstrates that fixed-duration ibrutinib-venetoclax provides superior overall survival, progression-free survival, and safety compared to chlorambucil-obinutuzumab in older/comorbid CLL patients, with durable dise

Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance
Hematology-Oncologyibrutinib resistanceBệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemia

Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance

By MedXY|Sep 28, 2026

Aberrant MERTK expression activates BCR signaling via CD79a in CLL, offering a novel therapeutic target. Inhibiting MERTK with UNC-2025 shows potential against ibrutinib-resistant relapse, especially combined with venetoclax.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models